Tag Archives: Immunotherapy

FDA Approves Opdivo (nivolumab) + Yervoy (ipilimumab) as the First and Only Immunotherapy Treatment for Previously Untreated Unresectable Malignant Pleural Mesothelioma

PRINCETON, N.J.–(BUSINESS WIRE) October 2, 2020 — Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) 360 mg every three weeks plus Yervoy (ipilimumab) 1 mg/kg every six weeks (injections for intravenous use) was approved by the U.S. Food and Drug Administration (FDA) for the first-line treatment of adult patients with unresectable malignant pleural… Read More »

Medical News Today: Cancer: Using copper to boost immunotherapy

An interdisciplinary group of scientists has successfully destroyed tumor cells in mice by using nano-sized copper compounds alongside immunotherapy. Importantly, the tumors did not return after the treatment ceased. According to the World Health Organization, cancer is the second leading cause of death worldwide — in 2018, it was responsible for approximately 9.6 million deaths.… Read More »

GE Healthcare, VUMC join on cancer immunotherapy research

GE Healthcare and Vanderbilt University Medical Center will collaborate on enabling safer and more precise treatment of cancer immunotherapies. Under the during the five-year program, the organizations will analyze the immunotherapy treatment response of thousands of VUMC cancer patients by using anonymized demographic, genomic, tumor, cellular, proteomic and imaging data. Cancer immunotherapy is a treatment… Read More »

‘Simply cruel’: Patient advocates condemn breast cancer immunotherapy hype

In depth: Six tips for writing accurately about cancer immunotherapy drugs. “Increases life expectancy,” announced Newsweek. “Helped slow an aggressive type of breast cancer,” reported Reuters. “Expected to change the standard of care,” crowed The New York Times. Judging by news reports last weekend, women with metastatic triple-negative breast cancer had reason to cheer results of… Read More »